Literature DB >> 21138228

Delayed union of the clavicle treated with plasma rich in growth factors.

Roberto Seijas1, Romen Y Santana-Suarez, Montserrat Garcia-Balletbo, Xavier Cuscó, Oscar Ares, Ramón Cugat.   

Abstract

Nonunion is an uncommon complication of fracture of the clavicle; it is usually treated surgically. The use of biological treatments in this type of condition is increasingly more common because of their ease of application. Plasma rich in growth factors (PRGF) has been used in delayed healing and in nonunion of fractures. We report a case of delayed union fracture of the clavicle in which biological treatment was chosen before considering surgery. Three percutaneous injections of PRGF, one every 2 weeks, were delivered into the delayed union site. The autologous PGRF used was obtained through the patented PRGF system. Three months after the final dose, computed tomography study showed healing of the bone. The patient regained complete mobility of the shoulder without pain. Currently she is able to carry out all the normal life activities and experiences no pain.

Entities:  

Mesh:

Year:  2010        PMID: 21138228

Source DB:  PubMed          Journal:  Acta Orthop Belg        ISSN: 0001-6462            Impact factor:   0.500


  3 in total

1.  Arthroscopic management and platelet-rich plasma therapy for avascular necrosis of the hip.

Authors:  Jorge Guadilla; Nicolas Fiz; Isabel Andia; Mikel Sánchez
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-06-22       Impact factor: 4.342

2.  Platelet-rich plasma versus exchange intramedullary nailing in treatment of long bone oligotrophic nonunions.

Authors:  Altuğ Duramaz; Hüseyin Tamer Ursavaş; Mustafa Gökhan Bilgili; Alkan Bayrak; Berhan Bayram; Mustafa Cevdet Avkan
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-08-01

Review 3.  Platelet rich plasma and knee surgery.

Authors:  Mikel Sánchez; Diego Delgado; Pello Sánchez; Nicolás Fiz; Juan Azofra; Gorka Orive; Eduardo Anitua; Sabino Padilla
Journal:  Biomed Res Int       Date:  2014-09-02       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.